Table 3.

Analysis of risk factors for in-hospital mortality in patients with haematological malignancies

	ORs (CIs 95%)	P value
Thrombocytopenia at hospital admission1	1.2 (0.8–7.6)	0.212
Neutropenia at hospital admission2	3.1 (2.9–270)	< 0.001
Low albumin at hospital admission3	1.4 (0.9–6.6)	0.086
Days from admission to respiratory worsening*(> 10d)	4.1 (2.2–12.4)	< 0.001
Corticosteroids	1.7 (0.88–9.6)	0.154
Prior (30 d) infections6	7.7 (3.2–112)	< 0.001
PO2/FiO2 at respiratory worsening* (< 250)	1.2 (0.7–7.2)	0.082
Days from SARS-CoV-2 diagnosis to respiratory worsening (> 10-d)	2.8 (1.4–22.1)	0.014
Percentage of total lung parenchyma involvement variation (CT1-CT2)	2.6 (1.4–4.8)	0.004
Total CT score variation (CT1-CT2)	2.4 (1.2–12.2)	0.006
Active treatment in the last 90 days	4.4 (1.5–22.3)	< 0.001
Multiple myeloma	1.5 (1.1–3.3)	0.044

¹Thrombocytopenia was defined as platelets count < 150 × 10˄9/L; ²Neutropenia was defined as polymorphonuclear leukocytes count < 500 × 10˄9/L; ³level of serum albumin < 3.5 g/dl. *respiratory worsening was defined as: i) the need of supplementary oxygen therapy or ii) the need of increasing oxygen therapy supplementation in a patient with SARS-CoV2 infection for reasons directly related to the infection. A careful evaluation of causes of supplementary oxygen therapy for reasons other than SARS-CoV2 infection (i.e. cardiac failure, bacterial superinfections) was performed. In the case of doubt, a panel discussion was performed